Spero Therapeutics (SPRO) Enterprise Value (2016 - 2026)
Spero Therapeutics' (SPRO) quarterly Enterprise Value came in at -$56.1 million in Q1 2026, down 14.81% YoY from -$65.9 million in Q1 2025, and down 39.4% on a QoQ basis from -$40.3 million in Q4 2025.
Spero Therapeutics (SPRO) Enterprise Value (2016 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has 11 years of Enterprise Value data on file, last reported at -$56.1 million in Q1 2026.
- Quarterly Enterprise Value fell 14.81% year-over-year to -$56.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$56.1 million (down 14.81% YoY) and the FY2025 annual result came in at -$40.3 million, up 23.87% from the prior year.
- Enterprise Value slipped to -$56.1 million in Q1 2026, from -$40.3 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$31.2 million in Q2 2025 to a low of -$122.0 million in Q1 2022.
- A 5-year average of -$68.9 million and a median of -$63.5 million in 2024 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2022 — Enterprise Value surged 59.13% — and 2023, when it plunged 85.99%.
- Tracing SPRO's Enterprise Value over 5 years: stood at -$109.1 million in 2022, then soared by 30.04% to -$76.3 million in 2023, then jumped by 30.71% to -$52.9 million in 2024, then increased by 23.87% to -$40.3 million in 2025, then slumped by 39.4% to -$56.1 million in 2026.
- The last three Enterprise Value figures came in at -$56.1 million (Q1 2026), -$40.3 million (Q4 2025), and -$48.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Spero Therapeutics | 70.14 Mn | 19.37 Mn | - | -50.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -50.77 Mn |
| Mar 31, 2026 | -56.13 Mn |
| Dec 31, 2025 | -40.27 Mn |
| Sep 30, 2025 | -48.62 Mn |
| Jun 30, 2025 | -31.19 Mn |
| Mar 31, 2025 | -48.89 Mn |
| Dec 31, 2024 | -52.89 Mn |
| Sep 30, 2024 | -76.29 Mn |
| Jun 30, 2024 | -63.53 Mn |
| Mar 31, 2024 | -82.27 Mn |
| Dec 31, 2023 | -76.33 Mn |
| Sep 30, 2023 | -93.83 Mn |
| Jun 30, 2023 | -77.69 Mn |
| Mar 31, 2023 | -96.25 Mn |
| Dec 31, 2022 | -109.11 Mn |
| Sep 30, 2022 | -50.45 Mn |
| Jun 30, 2022 | -45.40 Mn |
| Mar 31, 2022 | -121.97 Mn |
| Dec 31, 2021 | -146.40 Mn |
| Sep 30, 2021 | -123.42 Mn |